The FDA focused on SSRIs due to their potential risks during pregnancy, highlighted by an expert panel consisting mainly of critics of these medications. Many panelists cited studies with inadequate controls, making it challenging to ascertain causation between SSRIs and health issues. Some experts suggested that risks associated with untreated depression were overlooked, despite it being a leading cause of maternal mortality. There are concerns that the panel's findings might deter women from necessary mental health treatments, as misinformation was prevalent during the discussions.
During a recent FDA panel, experts raised concerns about the safety of SSRIs during pregnancy, indicating a lack of robust studies to support claims against their use.
While discussing SSRIs, panelists failed to adequately weigh the risks of untreated depression, a significant factor contributing to maternal death within the first year postpartum.
Collection
[
|
...
]